ATS 2024 Final Program

Click on the session title to view the speakers

325

WEDNESDAY • MAY 22

904 Using Cough Sounds to Predict Chest Radiography Results 905 Cough-omics: Quantifying the Variability and Predictability of Daily Cough Countsin Persistent Coughers 906 Can Hypotonic Saline Cough Challenge Help Us to Understand Mechanisms of Cough in Idiopathic Pulmonary Fibrosis? 907 Camlipixant Reduces Burden of Cough-related Urinary Incontinence in Patients With Refractory Chronic Cough in Post-hoc Analysis of A Phase 2b Trial 908 Using Continuous Cough Monitoring to Assess Bronchiectasis Therapy 909 The Clinical Impacts of Pseudomonas Aeruginosa Isolation in Patients With Bronchiectasis: Insights From KMBARC Registry 910 Impact of Age in Hospital Mortality in ICU-admitted Bronchiectasis Patients 911 Clinical Characterization of Patients With COPD Bronchiectasis Overlap: Data From the US Bronchiectasis and NTM Research Registry 912 Association Between Exacerbation Burden and Comorbidities Among Patients With Non-Cystic Fibrosis Bronchiectasis Over 1 Year 913 A Phase 1 Study of Brensocatib Following a Single Oral Administration in Subjects With or Without Renal Impairment 914 Symptom Phenotyping in Adults With Cystic Fibrosis During a Large Randomized Clinical Trial 915 Finger on the Pulse: A Single Center Snapshot of Cardiovascular Health in Adults With Cystic Fibrosis 916 Non-invasive Ventilation in Cystic Fibrosis: A 23-year Analysis of the Australian Cystic Fibrosis Data Registry 917 Breath Biopsy ® Reveals Promising VOC Biomarkers for Early Detection and Monitoring of Acute Pulmonary Exacerbations in People With Cystic Fibrosis

919 Effects of Trikafta on Important Markers of Cystic Fibrosis-Related Liver Disease 920 Long-term Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy in Cystic Fibrosis on Pulmonary Function, Nutritional Status, Exacerbations, Quality of Life, Exercise Capacity, and Sweat Chloride: A Single-center Study 921 Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant 922 Diet Composition and Elexacaftor-Tezacaftor-Ivacaftor Concentrations in People With Cystic Fibrosis 923 Gender-based Disparities in Trikafta Efficacy for Cystic Fibrosis Patients 924 The Case of 7T: Clinical Insights on the Intronic 7T Variant in the CFTR Gene 925 Brain Ventricular Volumes Are Not Increased in Patients With Primary Ciliary Dyskinesia

BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

D26 UNVEILING CONNECTIONS: TOBACCO, CANNABIS,

E-CIGARETTES, AND RESPIRATORY HEALTH INSIGHTS

8:15 a.m. - 10:15 a.m.

San Diego Convention Center Room 6E (Upper Level)

Poster Viewing

8:15-9:00 9:00-10:15

Discussion

1001 Identification of a Dietary Pattern for Lung Epigenetic Aging and Its Associations With Lung Health and Mortality in Ever Smokers 1002 Social Determinants of Health Associated With Frailty in Smokers: Analysis of the COPDGene Cohort 1003 Frailty Is Associated With Respiratory Exacerbations and Mortality in Smokers With and Without COPD

918 Extrapulmonary Effects of

Elexacaftor/Tezacaftor/Ivacaftor After One Year and Trends in Future Care

ATS 2024 • San Diego, CA